MS4A1 and lymphoma: The current treatment of PTLDs includes the tapering of immunosuppression (reducing the dose of the immunosuppressive agents) combined with immunotherapy with anti-CD20 monoclonal antibodies to target lymphoma cells, which in most cases express the CD20 receptor on their surface [5].